Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 0.0803 USD -15.56% Market Closed
Market Cap: 21.3m USD

Relative Value

The Relative Value of one ADAP stock under the Base Case scenario is 1.2439 USD. Compared to the current market price of 0.0803 USD, Adaptimmune Therapeutics PLC is Undervalued by 94%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ADAP Relative Value
Base Case
1.2439 USD
Undervaluation 94%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
91
Median 3Y
3.4
Median 5Y
17
Industry
7.5
Forward
0.4
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-2.9
Industry
24.4
Forward
-0.2
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-3.1
Industry
20.6
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-7.1
Industry
23
vs History
vs Industry
62
Median 3Y
3.4
Median 5Y
3.6
Industry
2.8
vs History
80
vs Industry
41
Median 3Y
1
Median 5Y
8.6
Industry
8
Forward
-0.3
vs History
0
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.2
vs History
vs Industry
15
Median 3Y
-1.1
Median 5Y
-1.5
Industry
5
Forward
0.1
vs History
vs Industry
14
Median 3Y
-1
Median 5Y
-1.4
Industry
5
Forward
0.1
vs History
vs Industry
20
Median 3Y
-1
Median 5Y
-1.7
Industry
5.5
vs History
vs Industry
16
Median 3Y
-1
Median 5Y
-1.9
Industry
3.9
vs History
74
vs Industry
52
Median 3Y
0.9
Median 5Y
1.6
Industry
5

Multiples Across Competitors

ADAP Competitors Multiples
Adaptimmune Therapeutics PLC Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
21.3m USD 0.1 -0.3 0.4 0.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 024 170.8 -161 711.8 -196 369.8 -194 128.9
US
Abbvie Inc
NYSE:ABBV
346.7B USD 6 83.4 15.8 23.4
US
Amgen Inc
NASDAQ:AMGN
153.2B USD 4.4 23.1 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
137.3B USD 4.8 23 10 13.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 070.6 -528.4 -575.3 -560
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
98.8B USD 8.7 27.2 20 20.9
AU
CSL Ltd
ASX:CSL
128.6B AUD 5.5 30.4 18.6 23.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.1B USD 4.2 13.2 11.9 13.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
56.1B USD 22.8 -175.7 -438.6 -301.1
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -61.2 -65.9 -59.5
P/E Multiple
Earnings Growth PEG
UK
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Average P/E: 33.4
Negative Multiple: -0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 711.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
83.4
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
23.1
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
23
189%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.4 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
N/A N/A
AU
CSL Ltd
ASX:CSL
30.4
16%
1.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -175.7 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Average EV/EBITDA: 13.6
0.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 369.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.8
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.3 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20
17%
1.2
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.9
11%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -438.6 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Average EV/EBIT: 16.2
0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 128.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.9
17%
1.2
AU
CSL Ltd
ASX:CSL
23.3
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
11%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -301.1 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A N/A